Novo Nordisk CEO steps down due to concerns in obesity drug market.

From Yahoo Finance: 2025-05-16 08:21:00

Novo Nordisk CEO Lars Fruergaard Jorgensen steps down, citing concerns about losing competitive edge in obesity drug market. Analysts express surprise and worry over stock decline and CEO transition, questioning Novo’s strategic direction. Investors express uncertainty over Novo’s future, with concerns about market position vs. Eli Lilly and emerging competitors. Novo Nordisk Foundation increases influence, appointing chairman as observer on board without changing company strategy. Novo shareholder Markus Manns raises concerns over deeper issues affecting Novo’s recovery. UBS analyst Trung Huynh highlights CEO’s past growth but emphasizes need for understanding the U.S. system for successor. Tema ETFs CIO Yuri Khodjamirian underscores Novo’s need to improve competitive positioning against Eli Lilly, highlighting Lilly’s advantage in U.S. market strategy and partnerships.



Read more at Yahoo Finance: Novo Nordisk CEO’s surprise exit after setbacks in weight-loss market